Facet Biotech Announces November 3 Webcast of Third Quarter 2009 Financial Results Conference Call

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

Q3 2009 FACET BIOTECH CORP Earnings Release - After Market Close

Earnings Announcements for Tuesday, November 3CompanySymbolTimeConferenceCall3D SystemsTDSCAfter Market CloseListenAbengoaABG.MC11:45 pm ETListenAcorda TherapeuticsACORBefore Market OpenListenAECON GROUP INCARE.TOAfter Market CloseAGA Medical Holdings, Inc.AGAMAfter Market CloseListenAllis-Chalmers Energy Inc.ALYBefore Market OpenAllos Therapeutics, Inc.ALTHAfter Market CloseListenAlpha Natural Resources, Inc.ANRBefore Market OpenAmerican Capital Ltd.ACASAfter Market CloseListenAmerican Tower Corp.AMT07:00 am ETListenAmeriSourceBergenABCBefore Market OpenListenAMICAS INCAMCSAfter Market CloseAMTRUST FINANCIAL SERVICES INCAFSIAfter Market CloseANIMAL HEALTH INTERNATIONAL INCAHIITime Not SuppliedAnoto Group ABAOTOF.PK02:30 am ETAnworth Mortgage Asset...
Click here to read the whole Article (external link)

FACET BIOTECH CORP Files SEC form 8-K, Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 26, 2009, Facet Biotech Corporation ("Facet") and EKR Therapeutics, Inc. ("EKR") entered into Amendment No. 2 to Asset Purchase Agreement ("Amendment No. 2"), which amends that certain Asset Purchase Agreement (the "Asset Purchase Agreement") with an effective date of February 4, 2008, as amended March 7, 2008, between Facet and EKR. Amendment No. 2 has an effective date of October 19, 2009. Amendment No. 2 amends certain provisions of the Asset Purchase Agreement and, among other things, (i) requires EKR to pay to Facet a one-time, non-refundable, non-creditable fee of $2,000,000; (ii) increases, retroactively effective to July 1, 2009, the royalty rate on Net Sales (as defined in the Asset Purchase Agreement) of the Cardene PMB Product (as defined in the Asset Purchase Agreement) from a flat rate of 10% to the tiered royalty structure set forth below: (iii) extends the royalty term for royalties on net sales of the Cardene PMB Product from December 31, 2014 to December 31, 2017; (iv) provides that upon the Successful Launch of a Generic PMB Product (as defined in the Asset Purchase Agreement) the applicable royalty rate on net sales of the Cardene PMB Product would be reduced by 50% instead of terminating EKR's obligation to pay such royalties; (v) provides payment to Facet of 20% of all consideration and contingent payments, whether in cash or in kind, received by EKR under outlicenses and distribution agreements covering the Cardene PMB Product; (vi) eliminates EKR's obligation to pay two $30,000,000 milestone payments, which would have been payable if and when EKR achieved Net Sales of the Cardene PMB Product (as defined in the Asset Purchase Agreement) in any 12 consecutive month period of more than $80,000,000 and $150,000,000, respectively; and (vii) provides a specific acknowledgement by EKR of its obli...
Click here to read the whole Article (external link)

FACET BIOTECH CORP Earnings Call scheduled for 4:30 pm ET today

Call DetailsFACET BIOTECH CORP Earnings Conference Call (Q3 2009)Tue, Nov 3, 2009, 4:30 pm EasternAbout FACET BIOTECH CORP (NasdaqGM:FACT)Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California. Facet Biotech Corporation operates independently of PDL BioPharma Inc. as of December 18, 2008.More Info:Quote |Chart |News |Profile |Reports |Research |SEC |Insider |...
Click here to read the whole Article (external link)

FACET BIOTECH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi

Show all filings for FACET BIOTECH CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for FACET BIOTECH CORP 3-Nov-2009Results of Operations and Financial Condition, Financial Statements and Exhibi Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provide...
Click here to read the whole Article (external link)

Facet Biotech Reports Third Quarter 2009 Financial Results

REDWOOD CITY, CA--(Marketwire - 11/03/09) - Facet Biotech Corporation (NASDAQ:FACT - News) today reported financial results for the third quarter ended September 30, 2009. "We are executing on our development programs while remaining vigilant on cost containment and expense management," said Faheem Hasnain, president and chief executive officer of Facet Biotech. "We expect our lead program, daclizumab in multiple sclerosis, to enter a second registration-enabling study in the first half of 2010, triggering a $30 million milestone payment to us from Biogen Idec. Our four development-stage oncology programs continue to progress, and for our elotuzumab and TRU-016 oncology programs, we remain on track toward achieving important development milestones in the coming year. Our strong balance sheet enables us to support our programs through these and other future critical milestones to the end of 2012. We possess a focused and promising pipeline and have never been more confident in the future growth prospects for Facet Biotech."Summary of Financial ResultsThe financial results for the quarter ended September 30, 2009 represent the third full quarter of operations for Facet as an independent company since its spin-off from PDL BioPharma, Inc. (PDL) on December 18, 2008. The results for the quarter and nine months ended September 30, 2008 are comprised of the results of PDL's former biotechnology operations, which were derived from PDL's historical consolidated financial statements, prior to the spin-off.� -- Total re...
Click here to read the whole Article (external link)

FACET BIOTECH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi

Show all filings for FACET BIOTECH CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for FACET BIOTECH CORP 4-Nov-2009Results of Operations and Financial Condition, Financial Statements and Exhibi Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provide...
Click here to read the whole Article (external link)

New Star Analyst Rankings for Facet Biotech Corporation

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...
Click here to read the whole Article (external link)